Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
<h3>Background</h3><p dir="ltr">Triple-Negative Breast Cancer (TNBC) is a lethal subtype of breast cancer with limited treatment options. The purpose of this Network Meta-Analysis (NMA) is to compare the efficacy and safety of inhibitors of programmed cell death 1 (PD-1)...
محفوظ في:
| المؤلف الرئيسي: | Ibrahim Elmakaty (14614270) (author) |
|---|---|
| مؤلفون آخرون: | Ruba Abdo (15455318) (author), Ahmed Elsabagh (15455321) (author), Abdelrahman Elsayed (6288913) (author), Mohammed Imad Malki (9649555) (author) |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
حسب: Afsheen Raza (492657)
منشور في: (2023) -
Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
حسب: Maha, Al-Asmakh
منشور في: (2020) -
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
حسب: Allan Relecom (14153295)
منشور في: (2021)